PDUFA Stocks

[mcjodie]

$SLGL - PDUFA DATE April 26, 2021
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.

Seeking approval for Epsolay, a 5% microencapsulated benzoyl peroxide cream, and, if approved, could be the first single-agent benzoyl peroxide prescription drug approved by the FDA, according to a press release form Sol-Gel.1

The FDA initially accepted the New Drug Application (NDA) filing for Epsolay in September 2021, and is supported by positive data from 2 phase 3 trials investigating the safety and efficacy of Epsolay in patients with PPR.

Price as of posting $14.43